The big news out of this year's TCT meeting in September wasn't really news at all. The final results of the SIRIUS clinical trial, assessing restenosis rates and other clinical measures of the sirolimus-coated drug-eluting stent (now being marketed in Europe by Cordis Corp. , a Johnson & Johnson operating company and soon to be available in the US) weren't all that different from the preliminary data previewed in May at the Paris Course on Revascularization. (See "For Drug-Eluting Stents, How Full is the Cup?" IN VIVO, May 2002 Also see "For Drug-Eluting Stents, How Full is the Cup?" - In Vivo, 1 May, 2002..)
The final results of SIRIUS, while not achieving the 0% in-stent restenosis and target vessel revascularization rates of earlier studies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?